Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gatifloxacin resistance and mutations in gyra after unsuccessful Helicobacter pylori eradication in Japan.

Antimicrobial agents and chemotherapy - 1 Apr 2006

Nishizawa Toshihiro, Suzuki Hidekazu, Kurabayashi Kumiko, Masaoka Tatsuhiro, Muraoka Hiroe, Mori Mikiji, Iwasaki Eisuke, Kobayashi Intetsu, Hibi Toshifumi

Abstract excerpt

A high resistance rate (47.9%) to gatifloxacin (GAT; 8-methoxy fluoroquinolone) in Helicobacter pylori (H. pylori) strains from 48 Japanese patients is observed after unsuccessful H. pylori eradication. A significant association between MICs for GAT equal to or above 1 microg/ml and mutations of the gyrA gene of H. pylori was demonstrated.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Infective Agents
Share to DNA Gyrase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Bacterial

Share to Fluoroquinolones

Share to Helicobacter pylori

Share to Helicobacter pylori-related gastroenterology studies

Share to Microbial Sensitivity Tests

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 16569878
DOI: 10.1128/AAC.50.4.1538-1540.2006
PMCID: PMC1426923

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gatifloxacin resistance and mutations in gyra after unsuccessful Helicobacter pylori eradication in Japan.PMID 16569878Read ↗

Gatifloxacin-based triple therapy as a third-line regimen for Helicobacter pylori eradication.Semantic proximity Read ↗

Acquisition of double mutation in gyrA caused high resistance to sitafloxacin in Helicobacter pylori after unsuccessful eradication with sitafloxacin-containing regimensSemantic proximity Read ↗

Gemifloxacin can partially overcome quinolone resistance of H. pylori with gyrA mutation in Taiwan.Semantic proximity Read ↗

Efficacy of sitafloxacin-based rescue therapy for Helicobacter pylori after failures of first- and second-line therapies.Semantic proximity Read ↗

Sitafloxacin resistance in Helicobacter pylori isolates and sitafloxacin-based triple therapy as a third-line regimen in Japan.Semantic proximity Read ↗

Update on quinolone-containing rescue therapies for Helicobacter pylori infection.Semantic proximity Read ↗

Rapid detection of point mutations conferring resistance to fluoroquinolone in gyrA of Helicobacter pylori by allele-specific PCR.Semantic proximity Read ↗

Sitafloxacin and Garenoxacin May Overcome the Antibiotic Resistance of <i>Helicobacter pylori</i> with <i>gyrA</i> MutationSemantic proximity Read ↗

Antibacterial Activity of Gatifloxacin (AM-1155, CG5501, BMS-206584), a Newly Developed Fluoroquinolone, against Sequentially Acquired Quinolone-Resistant Mutants and the norA Transformant of Staphylococcus aureusSemantic proximity Read ↗

Single and double mutations in gyrA but not in gyrB are associated with low- and high-level fluoroquinolone resistance in Helicobacter pylori.Semantic proximity Read ↗

Sitafloxacin activity against Helicobacter pylori isolates, including those with gyrA mutations.Semantic proximity Read ↗

Sitafloxacin-based third-line rescue regimens for Helicobacter pylori infection in Japan.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.